BMS-955176: Difference between revisions

'''BMS-955176''' is an experimental second generation [[HIV]] [[maturation inhibitor]] under [[drug development|development]] by [[Bristol-Myers Squibb]] for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.<ref>{{cite web|url=http://www.aidsmeds.com/articles/BMS_maturation_inhibitor_1667_26859.shtml|title=BMS Maturation Inhibitor Is Potent Against HIV in Early Trial|date=25 February 2015|access-date=22 July 2015|archive-url=https://web.archive.org/web/20150723033900/http://www.aidsmeds.com/articles/BMS_maturation_inhibitor_1667_26859.shtml|archive-date=23 July 2015|url-status=dead}}</ref> First generation maturation inhibitors such as [[bevirimat]] were ineffective against some naturally occurring changes (polymorphisms) in the [[Gag protease]] polyprotein; BMS-955176 has been selected to better tolerate gag [[Polymorphism (biology)|polymorphisms]].<ref>{{cite web|url=http://www.projectinform.org/hiv-news/croi2015-new-hiv-maturation-inhibitor-bms-955176-appears-more-potent-than-earlier-beviramat/|title=CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform}}</ref><ref>{{cite journal | vauthors = Wang D, Lu W, Li F | title = Pharmacological intervention of HIV-1 maturation | journal = Acta Pharmaceutica Sinica. B | volume = 5 | issue = 6 | pages = 493–9 | date = November 2015 | pmid = 26713265 | pmc = 4675807 | doi = 10.1016/j.apsb.2015.05.004 }}</ref>